NHS England | January 2019 | NHS Operational Planning and Contracting Guidance 2019/20
This is the full guidance, building on the first part published in December 2018. It accompanies five-year indicative CCG allocations and sets out the trust financial regime for 2019/20, alongside the service deliverables including those arising from year one of the Long Term Plan. CCGs and trusts should take action from April 2019 to begin implementing the measures set out in the LTP(Source:NHS England).
This summer, the Academy of Medical Royal Colleges, NICE, NHS Clinical Commissioners and NHS England and NHS Improvement joined forces to consult on how best to reduce the number of inappropriate interventions provided by the NHS. The consultation focused on 17 interventions resulting in clinical commissioning guidance for when the 17 interventions should be commissioned and offered.
The guidance will come into effect from 1 April 2019, however, changes to local systems and processes will need to be made ahead of that date to prevent any unintended consequences. The guidance and supporting information can be found on the NHS England Website
PHE, NICE, NHS England, HEARTUK & The British Heart Foundation| August 2018 | Familial Hypercholesterolaemia: implementation guide
A new implementation guide, written collaboratively by PHE, NICE, NHS England, HEARTUK and the British Heart Foundation, highlights that improving care for those with Familial Hypercholesterolaemia will need a co-ordinated effort and a whole-system approach.
Familial Hypercholesterolaemia (FH) is a genetic predisposition which more than 85% of people with FH in the UK are unaware that they have the condition and that they are at risk of premature heart disease. Untreated, people aged 20-39 with FH have a 100-fold increased risk of death from heart disease compared to those of a similar age without FH, and so early identification and treatment are absolutely crucial.
The new guide: Familial Hypercholesterolaemia: implementation guide, t
This guide IS aimed at local commissioners and service providers. By searching GP records for those at risk and offering DNA testing to family members of people diagnosed with FH we can start to address this hidden burden.
This implementation guide aims to provide practical support to organisations, helping them to identify the gaps in the provision of FH services in their local area, and helping them address these gaps in line with the recently updated NICE guidance.
a summary of recommendations from the recent update of the document
an outline of national and European policy documents
best practice case studies
(Source: PHE, NICE, NHS England, HEARTUK & The British Heart Foundation)
NHS England | April 2018 | Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs New guidance from NHS England for Clinical Commissioning Groups (CCGs ) to take the proposed conditions for which over the counter items (OTC) should not routinely be prescribed in primary care guidance into account in formulating local polices, and for prescribers to reflect local policies in their prescribing practice. Spending on OTC items for the year up to June 2017 was approximately £569 million on prescriptions for medicines, which could otherwise be purchased over the counter from a pharmacy and/or other outlets such as petrol stations or supermarkets.
These prescriptions include items for a condition:
That is considered to be self-limiting and so does not need treatment as it will heal or be cured of its own accord;
Which lends itself to self-care i.e. the person suffering does not normally need to seek medical advice and can manage the condition by purchasing OTC items directly.
These prescriptions also include other common items:
That can be purchased over the counter, sometimes at a lower cost than that which would be incurred by the NHS;
For which there is little evidence of clinical effectiveness.
NHS England gives the example that for every £1 million saved on prescriptions for OTC items could fund :
39 more community nurses; or
270 more hip replacements; or
66 more drug treatment courses for breast cancer; or
1000 more drug treatment courses for Alzheimer’s; or
NHS England & NHS Improvement | March 2018 | The Improving Access to Psychological Therapies (IAPT) Pathway for People with Long-term Physical Health Conditions and Medically Unexplained Symptoms
NHS England & NHS Improvement have developed, The Improving Access to Psychological Therapies (IAPT) Pathway for People with Long-term Physical Health Conditions and Medically Unexplained Symptoms. This guidance has been produced to support Clinical Commissioning Groups CCGs in expanding Improving Access to Psychological Therapies by commissioning (IAPT) services integrated into physical healthcare pathways. To facilitate this expansion, it sets out the treatment pathway that that underpins the access and waiting time standards, which all services should seek to measure themselves against.
From April 2018 all CCGs are expected to expand Improving Access to Psychological Therapies by commissioning (IAPT) services integrated into physical healthcare pathways (NHS England & NHS Improvement).
The General Data Protection Regulation (GDPR) is set to replace the existing Data Protection Act on 25 May 2018. It will require all organisations, which process personal data – including CCGs, to meet higher data protection standards.
Some of the new requirements of GDPR will be appointing a data protection officer, the ability to demonstrate that you are complying with the new law and higher penalties for those not following the rules.
The Information Commissioners Office has produced a package of tools and resources to help you get ready. These resources include: